Literature DB >> 21904102

Key concepts of clinical trials: a narrative review.

Craig A Umscheid1, David J Margolis, Craig E Grossman.   

Abstract

The recent focus of federal funding on comparative effectiveness research underscores the importance of clinical trials in the practice of evidence-based medicine and health care reform. The impact of clinical trials not only extends to the individual patient by establishing a broader selection of effective therapies, but also to society as a whole by enhancing the value of health care provided. However, clinical trials also have the potential to pose unknown risks to their participants, and biased knowledge extracted from flawed clinical trials may lead to the inadvertent harm of patients. Although conducting a well-designed clinical trial may appear straightforward, it is founded on rigorous methodology and oversight governed by key ethical principles. In this review, we provide an overview of the ethical foundations of trial design, trial oversight, and the process of obtaining approval of a therapeutic, from its pre-clinical phase to post-marketing surveillance. This narrative review is based on a course in clinical trials developed by one of the authors (DJM), and is supplemented by a PubMed search predating January 2011 using the keywords "randomized controlled trial," "patient/clinical research," "ethics," "phase IV," "data and safety monitoring board," and "surrogate endpoint." With an understanding of the key principles in designing and implementing clinical trials, health care providers can partner with the pharmaceutical industry and regulatory bodies to effectively compare medical therapies and thereby meet one of the essential goals of health care reform.

Entities:  

Mesh:

Year:  2011        PMID: 21904102      PMCID: PMC3272827          DOI: 10.3810/pgm.2011.09.2475

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  42 in total

Review 1.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

Authors:  D Moher; K F Schulz; D Altman
Journal:  JAMA       Date:  2001-04-18       Impact factor: 56.272

2.  Timing of new black box warnings and withdrawals for prescription medications.

Authors:  Karen E Lasser; Paul D Allen; Steffie J Woolhandler; David U Himmelstein; Sidney M Wolfe; David H Bor
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

Review 3.  Biomarkers and surrogate end points--the challenge of statistical validation.

Authors:  Marc Buyse; Daniel J Sargent; Axel Grothey; Alastair Matheson; Aimery de Gramont
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

Review 4.  Strategies to improve recruitment to research studies.

Authors:  J Mapstone; D Elbourne; I Roberts
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

Review 5.  Not all placebos are the same: a debate on the ethics of placebo use in clinical trials versus clinical practice.

Authors:  Alex Cahana; Simone Romagnioli
Journal:  J Anesth       Date:  2007-01-30       Impact factor: 2.078

Review 6.  Exploring the use of the sham design for interventional trials: implications for endoscopic research.

Authors:  C Mel Wilcox
Journal:  Gastrointest Endosc       Date:  2008-01       Impact factor: 9.427

7.  Probability of adverse events that have not yet occurred: a statistical reminder.

Authors:  E Eypasch; R Lefering; C K Kum; H Troidl
Journal:  BMJ       Date:  1995-09-02

8.  Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

Authors:  Thomas G Roberts; Bernardo H Goulart; Lee Squitieri; Sarah C Stallings; Elkan F Halpern; Bruce A Chabner; G Scott Gazelle; Stan N Finkelstein; Jeffrey W Clark
Journal:  JAMA       Date:  2004-11-03       Impact factor: 56.272

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

10.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  BMJ       Date:  2010-03-23
View more
  51 in total

1.  Randomized Controlled Trials 1: Design.

Authors:  Bryan M Curtis; Brendan J Barrett; Patrick S Parfrey
Journal:  Methods Mol Biol       Date:  2021

2.  Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.

Authors:  Stefan Willmann; Liping Zhang; Hannah Mayer; Hans-Ulrich Siegmund; Takahiko Tanigawa; Masato Kaneko; Gary Peters; Jeffrey I Weitz; Scott D Berkowitz; Rolf Burghaus
Journal:  Blood Adv       Date:  2018-11-27

Review 3.  Nematodes and human therapeutic trials for inflammatory disease.

Authors:  D E Elliott; J V Weinstock
Journal:  Parasite Immunol       Date:  2017-04-18       Impact factor: 2.280

4.  Time-trend impact on treatment estimation in two-arm clinical trials with a binary outcome and Bayesian response adaptive randomization.

Authors:  Yunyun Jiang; Wenle Zhao; Valerie Durkalski-Mauldin
Journal:  J Biopharm Stat       Date:  2019-04-24       Impact factor: 1.051

5.  Confronting Racism in All Forms of Pain Research: Reframing Study Designs.

Authors:  Janelle E Letzen; Vani A Mathur; Mary R Janevic; Michael D Burton; Anna M Hood; Calia A Morais; Staja Q Booker; Claudia M Campbell; Edwin N Aroke; Burel R Goodin; Lisa C Campbell; Ericka N Merriwether
Journal:  J Pain       Date:  2022-02-26       Impact factor: 5.383

6.  Consensus practice guidelines on interventions for lumbar facet joint pain from a multispecialty, international working group.

Authors:  Steven P Cohen; Arun Bhaskar; Anuj Bhatia; Asokumar Buvanendran; Tim Deer; Shuchita Garg; W Michael Hooten; Robert W Hurley; David J Kennedy; Brian C McLean; Jee Youn Moon; Samer Narouze; Sanjog Pangarkar; David Anthony Provenzano; Richard Rauck; B Todd Sitzman; Matthew Smuck; Jan van Zundert; Kevin Vorenkamp; Mark S Wallace; Zirong Zhao
Journal:  Reg Anesth Pain Med       Date:  2020-04-03       Impact factor: 6.288

Review 7.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

8.  A Modern Radiotherapy Series of Survival in Hispanic Patients with Glioblastoma.

Authors:  Cheng-Chia Wu; Tony J C Wang; Ashish Jani; Juan P Estrada; Timothy Ung; Daniel S Chow; Jennifer E Soun; Shumaila Saad; Yasir H Qureshi; Robyn Gartrell; Heva J Saadatmand; Anurag Saraf; Matthew D Garrett; Christopher S Grubb; Steven R Isaacson; Simon K Cheng; Michael B Sisti; Jeffrey N Bruce; Sameer A Sheth; Andrew B Lassman; Guy M McKhann
Journal:  World Neurosurg       Date:  2015-12-31       Impact factor: 2.104

9.  Comparative poisson clinical trials of multiple experimental treatments vs a single control using the negative multinomial distribution.

Authors:  Joseph A Chiarappa; Donald R Hoover
Journal:  Stat Med       Date:  2021-03-02       Impact factor: 2.497

Review 10.  Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.

Authors:  Nirmala Tilija Pun; Chul-Ho Jeong
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.